Gupta Shalabh K. 4/A

What Happened
Shalabh K. Gupta, CEO and Director of Unicycive Therapeutics, was granted 762,200 restricted stock units (reported as a derivative award) on May 14, 2026. The filing shows an acquisition at $0.00 per share (i.e., RSU award payable in common stock). This is a compensation grant (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Form 4 filed as an AMENDED filing on 2026-06-15 (about one month after the transaction).
• Transaction type/code: Award/Grant (A); derivative RSU award payable in common stock.
• Shares/price: 762,200 RSUs granted at $0.00 per unit.
• Vesting (per footnote): 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to continued service. The filing does not detail vesting for the full 762,200 in the provided footnote.
• Shares owned after transaction: not specified in the excerpted filing.

Context
RSU grants are standard executive compensation and typically convert into common shares as they vest, which can dilute existing shareholders when settled. Because this is a grant rather than a purchase or sale, it should be viewed as compensation disclosure rather than a direct signal of the insider buying or selling stock. The filing was amended and submitted about a month after the reported grant date.